EP0799222A1 - Piperazine 2,5 dione derivatives as modulators of multi-drug resistance - Google Patents

Piperazine 2,5 dione derivatives as modulators of multi-drug resistance

Info

Publication number
EP0799222A1
EP0799222A1 EP95941797A EP95941797A EP0799222A1 EP 0799222 A1 EP0799222 A1 EP 0799222A1 EP 95941797 A EP95941797 A EP 95941797A EP 95941797 A EP95941797 A EP 95941797A EP 0799222 A1 EP0799222 A1 EP 0799222A1
Authority
EP
European Patent Office
Prior art keywords
dimethoxy
tetrahydro
isoquinolyl
dioxo
methylbenzamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP95941797A
Other languages
German (de)
English (en)
French (fr)
Inventor
Philip Anthony Ashworth
Sukhjit Hunjan
Ian Andrew Pretswell
Hamish Ryder
Stephen James Brocchini
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xenova Ltd
Original Assignee
Xenova Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xenova Ltd filed Critical Xenova Ltd
Publication of EP0799222A1 publication Critical patent/EP0799222A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Definitions

  • the present invention relates to compounds useful as modulators of multi-drug resistance (MDR) , to their preparation and to pharmaceutical and veterinary compositions containing them.
  • MDR multi-drug resistance
  • tumours to treatment with certain cytotoxic agents is an obstacle to the successful chemotherapeutic treatment of cancer patients.
  • a tumour may acquire resistance to a cytotoxic agent used in a previous* treatment.
  • a tumour may also manifest intrinsic resistance, or cross-resistance, to a cytotoxic agent to which it has not previously been exposed, that agent being unrelated by structure or mechanism of action to any agent used in previous treatments of the tumour.
  • certain pathogens may acquire resistance to pharmaceutical agents used in previous treatments of the diseases or disorders to which those pathogens give rise.
  • Pathogens may also manifest intrinsic resistance, or cross resistance, to pharmaceutical agents to which they have not previously been exposed. Examples of this effect include multi-drug resistant forms of malaria, tuberculosis, leishmaniasis and amoebic dysentery.
  • MDR multi-drug resistance
  • P-gp plasma membrane glycoprotein
  • Certain agents which have the capacity to modulate MDR may therefore also be useful in facilitating the delivery of drugs across the blood brain barrier, and in treating AIDS and AIDS-related complex.
  • RMAs resistance modifying agents
  • R x is (i) a group
  • each of Ra to Re which may be the same or different, is independently selected from hydrogen, Ci-Cg alkyl unsubstituted or substituted by one or more halogen atoms, C 1 -C 8 alkenyl, C x -Cg alkoxy, C x -C 6 alkylthio, halogen, hydroxy, nitro, optionally substituted phenyl, cyano, -CH 2 OH, -CH 2 COOH,
  • n is 0 or is an integer of from 1 to 6, each of R 11 and R 12 is independently H or Cj-Cg alkyl and R 13 is C x -C 6 alkyl; or any of Ra and Rb, Rb and Re, Re and Rd or Rd and Re together form a methylenedioxy group, or form together with the carbon atoms to which they are attached a benzene ring which is optionally substituted; (ii) a 5- or 6-membered heterocyclic group containing at least one heteroatom selected from O, N and S, which group may be fused to a benzene ring;
  • R 2 is H, C- L -Cg alkyl optionally substituted by a group -N(R 11 R 12 ) as defined above, C 3 -C 6 cycloalkyl, C 2 - C 6 alkenyl, -COOR 11 wherein R 11 is as defined above or a phenyl group as defined under (i) above, but is other than H when R 1 is unsubstituted phenyl; and one of R 3 and R 4 is hydrogen and the other is a group of formula (A) :
  • R 5 and R 6 which may be the same or different, are each H or Cj-Cg alkoxy, or R 5 and R 6 together form a methylenedioxy group; and is a double bond or, when R ⁇ is as defined under
  • a Ci-Cg alkyl group may be linear or branched.
  • a Cj-Cg alkyl group is typically a C ⁇ C ⁇ alkyl group, for example a methyl, ethyl, propyl, i-propyl, n-butyl, sec-butyl or tert- butyl group.
  • a C 3 -C 6 cycloalkyl group may be cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl .
  • a halogen is, for example, fluorine, chlorine, bromine or iodine.
  • a C j -C 8 alkoxy group is typically a C ⁇ C, alkoxy group, for example a methoxy, ethoxy, propoxy, i-propoxy, n-butoxy, sec-butoxy or tert-butoxy group.
  • a C 2 -C 6 alkenyl group is, for example, C 2 -C 4 alkenyl, for example ethenyl, prop-1-enyl or prop-2-enyl.
  • a heterocyclic group may be, for example, a pyridine, pyrrole, furan or thiophene group which is linked via any one of its constituent ring atoms. It may be, for instance, a 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-furyl, 3-furyl, 2- thienyl or 3-thienyl group.
  • the integer q is from 1 to 4, and is preferably 1 or 2.
  • R 5 and R 6 are preferably the same and are preferably C 1 - C 4 alkyl, for instance methyl.
  • the phenyl group is unsubstituted or is substituted at one or more of positions 2 to 6. When it is mono-substituted it may carry the substituent at any one of positions 2 to 6, for instance position 3 or 4, especially position 4.
  • one of Ra to Re is other than hydrogen, preferably Rb or Re, especially Re.
  • the substituent Ra to Re is preferably selected from a halogen, for instance chlorine, bromine or fluorine; a C j -Cg alkoxy group, for instance OMe; and an acetamido group -NHAc in which Ac denotes acetyl .
  • the phenyl group may instead be 2,3-, 2,4-, 2,5-, 2,6-, 3,4- or 3,5- disubstituted, or 2,3,4-, 2,3,5-, 2,3,6- or
  • Ra to Re When it is disubstituted, three of Ra to Re are hydrogen and two are other than hydrogen.
  • Ra and Rb, or Ra and Re, or Ra and Rd, or Ra and Re, or Rb and Re, or Rb and Rd are other than hydrogen whilst, in each case, the other three of Ra to Re are hydrogen.
  • Ra to Re When the phenyl group is trisubstituted, two of Ra to Re are hydrogen and three are other than hydrogen.
  • Ra, Rb and Re, or Ra, Rb and Rd, or Ra, Rb and Re, or Rb, Re and Rd are other than hydrogen whilst, in each case, the other two of Ra to Re are hydrogen.
  • each of Ra to Re is hydrogen.
  • one of Ra to Re is selected from hydroxy, alkoxy, NHCOR 11 , -COjR 11 , -N(R 11 R 12 ) , -O(CH 2 ) n N(R X1 R 12 ) , -S0 2 R 13 , -CON R ⁇ R 12 ) , N0 2 , -SO ⁇ R ⁇ R 12 ) , -SOR 13 , -N(R 11 ) COR 12 and halogen and the other four of Ra to Re are H.
  • Alkoxy may be, for instance, OMe or OBu n .
  • NHCOR 11 is typically -NHAc.
  • C0 2 R 1X is typically -COOH or -COOMe.
  • NlR ⁇ R 12 ) is typically NMe 2 .
  • -CON(R xl R 12 ) may be -CONH 2 .
  • S0 2 R 13 is typically S0 2 Me, S0 2 N(R 11 R 12 ) is for example -S0 2 NMe 2 .
  • SOR 13 may be SOMe and -N(R lx )COR 12 may be -NMeCOBuX Halogen is typically F or Cl.
  • Re is alkoxy, especially OMe or OBu n ; NHCOR 11 , especially -NHAc; -CO-jR 11 , especially -C0 2 H or -C0 2 Me; -CO IR ⁇ R 12 ) especially -CONH 2 ; N0 2 ; N(R"R 12 ) especially NMe 2 ; -SOR 13 especially -SOMe; -S0 2 N(R R 12 ) especially -S0 2 NMe 2 or halogen, especially F or Cl; and each of Ra, Rb, Rd and Re is H.
  • Ra to Re are all hydrogen, or one or two of Ra to Re are other than hydrogen whilst the others are hydrogen.
  • one of Ra, Rb and Re is other than hydrogen.
  • Ra and Re, or Rb and Re are other than hydrogen.
  • Preferred values for the one or two of Ra to Re which is or are other than hydrogen include alkoxy such as OMe or OBu n , halogen such as Cl or F, hydroxy, -N(R R 12 ), -C0 2 R n , -CH 2 SCOR 13 , -CH- j SR 11 , -NHCOR 11 , -O(CH 2 ) n N(R X1 R 12 ) , -0(CH 2 ) ⁇ C0 2 R 11 , -CH 2 NHCO(CH 2 ) n C0 2 R n , -NHCOC ⁇ OR 11 , -NHCOCH 2 OCOR 13 , -CH 2 NHCOOR 13 and CF 3 .
  • Particularly preferred compounds are those wherein Ra,
  • ⁇ n i WESHEErmua, Rb, Rd and Re are each H, and Re is selected from H, OMe -NHAc, -C0 2 H, -C0 2 Me, -CONH 2 , N0 2 , -NMe 2 , S0 2 Me, -SOMe and -S0 2 NMe 2 .
  • Ra to Re are preferably each independently selected from H, halogen, hydroxy, alkoxy, nitro, -CH 2 SCOR 13 , -CH-jSR 11 , -C0 2 R 1X , -OCOR 13 , CF 3 , -0(CH 2 ) n N(R 11 R 12 ) , -O(CH 2 ) n C0 2 R 11 , -CH 2 NHCO(CH 2 ) n C0 2 R 11 , -NHCO(CH 2 ) n OR", -N(R 11 R 12 ) , -NHCOtCH- n OCOR 11 , -NHCO(CH 2 ) n C0 2 R 11 and -CH 2 NHC0 2 R 13 or Ra and Rb, Rb and Re, Re and Rd, or Rd and Re, form a methylenedioxy group or form, with the carbon atoms to which they are attached, an optionally substituted benzene ring.
  • Ra and Rb are independently H, nitro or halogen
  • Re is H, hydroxy, -O(CH 2 ) n N(R X1 R 12 ) , -OCOR 13 , -0 ( CR 2 ) n C0 2 R 11 , -CH 2 NHCO(CH 2 ) n C0 2 R 11 , alkoxy, -NHCO(CH 2 ) n OR 11 , -NHCO(CH 2 ) n OCOR 11 , -N(R 11 R 12 ) ,
  • Rd is H, halogen, alkoxy, -CH 2 SCOR 13 , -CHzSR 11 or -COjR 11 ; and Re is H, nitro or halogen.
  • R 1 is a phenyl group as defined above which is unsubstituted or mono-substituted at position 2, 3 or 4 by Cl or MeO, or is a pyridyl, furyl or
  • R 1 is unsubstituted phenyl
  • R 2 is 0* ⁇ 0 4 alkyl, preferably methyl, or is phenyl or cyclopropyl
  • R 3 is H
  • R" is a group of formula (A) wherein q is 2 and each of R 5 and R 6 is MeO.
  • R 1 is substituted phenyl as defined above or a furyl, thienyl or pyridyl group
  • R 2 is H
  • R 3 is H
  • R 4 is a group of formula (A) wherein q is 2 and each of R 5 and R 6 is MeO.
  • R 1 is substituted phenyl as defined above or a furyl, thienyl or pyridyl group
  • R 2 is H
  • R 3 is a group of formula (A) wherein q is 2 and each of R 5 and R 6 is MeO
  • R 4 is H.
  • R 1 is unsubstituted phenyl
  • R 2 is alkyl, preferably methyl, phenyl or cyclopropyl
  • R 3 is a group of formula (A) wherein q is 2 and each of R 5 and R 6 is MeO
  • R 4 is H.
  • R 1 is a furyl, thienyl or pyridyl group it is preferably a 3-furyl, 2-thienyl, 3- thienyl or 4-pyridyl group.
  • Examples of preferred compounds of the invention are as follows. The compound numbering is adhered to in the rest of the specification.
  • R 7 and R 8 is hydrogen and the other is -CHO, and q, r, R 5 and R 6 are as defined above; in the presence of a base in an organic solvent; and, if desired, converting the resulting compound into a pharmaceutically acceptable salt
  • Suitable bases include caesium carbonate, sodium carbonate, potassium carbonate, sodium hydride, potassium t- butoxide and triethylamine.
  • Suitable organic solvents include dimethylformamide
  • DMF tetrahydrofuran
  • THF tetrahydrofuran
  • the temperature is typically between 0°C and reflux temperature, for example from 80°C-95°C when caesium carbonate is used as base.
  • the reaction mixture is typically warmed from 0°C to room temperature, or to 40°C.
  • the reaction may be performed for a period of 1 to 4 hours, for example 2 or 3 hours.
  • the compounds of formula (II) wherein is a double bond are prepared by a process which comprises treating a compound of formula (IV) :
  • R 1 is as defined above, with an alkylating agent, in an organic solvent in the presence of a base.
  • the alkylating agent is typically an alkyl halide R 2 -CH 2 X, a methanesulphonate or p-toluenesulphonate ester R 2 CH 2 OS0 2 Me or R 2 CH 2 OS0 2 C 6 H 4 Me, respectively, or a dialkyl sulphate (R 2 CH 2 0) 2 S0 2 , wherein R 2 is as defined above and X is a halogen, for instance Cl Br or I.
  • Suitable bases and solvents include sodium hydride in THF or DMF or mixtures thereof, and potassium t-butoxide in t-butanol or THF or DMF or mixtures thereof.
  • the reaction mixture is typically warmed from 0°C to room temperature.
  • R 1 is as defined under (i) above and R 2 is as defined above with acetic anhydride.
  • the reaction is typically performed under reflux, for instance for 1 to 6 hours, typically 3 hours.
  • the compound of formula (X) may be prepared by treating a compound of formula (XI) :
  • the compounds of formula (XI) may be prepared by treating a compound of formula (XII) :
  • Compounds of formula (IV) may be prepared by a process which comprises treating 1,4-diacetyl-2, 5-piperazinedione of formula (V) :
  • R 1 is as defined above, in the presence of a base in an organic solvent .
  • Suitable bases and solvents include triethylamine, caesium carbonate, sodium carbonate, potassium carbonate and sodium hydride in DMF or THF or mixtures thereof, and potassium t-butoxide in t-butanol or DMF or THF or mixtures
  • the temperature of the reaction is typically from 100-140°C, for instance 120- 130°C.
  • potassium t-butoxide is used as base the reaction mixture is typically warmed from 0°C to room temperature.
  • the reaction is conducted in an organic solvent either with an excess of the amine of formula (IX) , or in the presence of a base such as a tertiary amine, e.g. Et 3 N, or pyridine.
  • the organic solvent is an inert organic solvent such as CH 2 C1 2 .
  • the coupling agent used in (a) or (b) with the 3- or 4- formylbenzoic acid, respectively, may be, for instance, 1- cyclohexyl-3- (2-morpholinoethyl) carbodiimide metho-p- toluenesulphonate or 2-chloro-l-methylpyridinium iodide.
  • the activated acid halide or mixed anhydride derivative of 3- or 4-formylbenzoic acid may be produced by conventional methods.
  • the acid halide derivative may be prepared by treatment of the carboxylic acid with a halogenating agent, for instance a chlorinating agent such as SOCl 2 , PC1 3 , oxalyl chloride or PC1 5 .
  • a halogenating agent for instance a chlorinating agent such as SOCl 2 , PC1 3 , oxalyl chloride or PC1 5 .
  • the mixed anhydride derivative may be prepared by treatment of the carboxylic acid with a Cj-Cg alkyl haloformate such as iBuOCOCl or EtOCOCl , in the presence of a base such as Et 3 N.
  • the reduction step (ii) is typically performed using iron powder and concentrated hydrochloric acid in methanol, usually at a temperature of about 80°C and for a period of 1 to 4 hours, for instance 3 hours. Alternatively it may be carried out by catalytic hydrogenation over a palladium on carbon catalyst in methanolic HCl, isopropanol or acetic acid.
  • Suitable salts include salts with pharmaceutically acceptable inorganic or organic acids.
  • inorganic acids include hydrochloric acid, sulphuric acid and orthophosphoric acid.
  • organic acids include -toluenesulphonic acid, methanesulphonic acid, mucic acid and succinic acid.
  • MDR cells which exhibit multi-drug resistance
  • MDR cells display a reduction in intracellular drug accumulation compared with the corresponding drug-sensitive cells.
  • Studies using jLn vitro derived MDR cell lines have shown that MDR is often associated with increased expression of a plasma membrane glycoprotein (P-gp) which has drug binding properties.
  • P-gp plasma membrane glycoprotein
  • P-gp is thought to function as an efflux pump for many hydrophobic compounds
  • transfection studies using cloned P-gp have shown that its overexpression can confer the MDR phenotype on cells: see, for example, Ann. Rev. Biochem . 58 . 137-171 (1989) .
  • P-gp A major function of P-gp in normal tissues is to export intracellular toxins from the cell.
  • overexpression of P-gp may play a clinical role in multi-drug resistance.
  • Increased levels of P-gp mRNA or protein have been detected in many forms of human cancers - leukaemias, lymphomas, sarcomas and carcinomas. Indeed, in some cases P-gp levels have been found to be increased in tumour biopsies obtained after relapse from chemotherapy.
  • Inhibition of P-gp function in P-gp mediated MDR has been shown to lead to a net accumulation of anti-cancer agent in the cells.
  • Verapamil a known calcium channel blocker was shown to sensitise MDR cells to Vinca alkaloids .in vitro and jLn vivo: Cancer Res. , 4.1, 1967-1972 (1981) .
  • the proposed mechanism of action involves competition with the anti-cancer agent for binding to the P- gp.
  • a range of structurally unrelated resistance-modifying agents acting by this mechanism have been described such as tamoxifen (Nolvadex: ICI) and related compounds, and cyclosporin A and derivatives.
  • the present compounds have been found in biological tests to have activity in modulating multi-drug resistance. The results are set out in Example 5 which follows.
  • the present compounds may therefore be used as multi-drug resistance modifying agents, also termed resistance-modifying agents, or RMAs.
  • the present compounds can modulate, e.g. reduce, or eliminate multi-drug resistance.
  • the present compounds can therefore be used in a method of potentiating the cytotoxicity of an agent which is cytotoxic to a tumour cell. Such a method comprises, for
  • the present compounds can also be used in a method of treating a disease in which the pathogen concerned exhibits multi-drug resistance, for instance multi-drug resistant forms of malaria (Plasmodium falciparum) . tuberculosis, leishmaniasis and amoebic dysentery.
  • a method of treating a disease in which the pathogen concerned exhibits multi-drug resistance for instance multi-drug resistant forms of malaria (Plasmodium falciparum) . tuberculosis, leishmaniasis and amoebic dysentery.
  • Such a method comprises, for instance, administering one of the present compounds with (separately, simultaneously or sequentially) the drug to which the pathogen concerned exhibits multi-drug resistance.
  • the therapeutic effect of the drug may thus be enhanced.
  • a human or animal patient harbouring a tumour may be treated for resistance to a chemotherapeutic agent by a method comprising the administration thereto of one of the present compounds.
  • the present compound is administered in an amount effective to potentiate the cytotoxicity of the said chemotherapeutic agent.
  • chemotherapeutic or antineoplastic agents which are preferred in the context of the present invention include Vinca alkaloids such as vincristine and vinblastine; anthracycline antibiotics such as daunorubicin and doxorubicin; mitoxantrone; actinomycin
  • a human or animal patient suffering from a disease in which the responsible pathogen exhibits multi- drug resistance may be treated for resistance to a therapeutic agent by a method comprising the administration thereto of one of the present compounds.
  • Examples of such disease include multi-drug resistant forms of malaria (Plasmodium falciparum) , tuberculosis, leishmaniasis and amoebic dysentery.
  • Posmodium falciparum multi-drug resistant forms of malaria
  • tuberculosis tuberculosis
  • leishmaniasis amoebic dysentery.
  • MDR modulators also have utility in the delivery of drugs across the blood-brain barrier, and in the treatment of AIDS and AIDS-related complex.
  • the present compounds can therefore be used in a method of facilitating the delivery of drugs across the blood brain barrier, and in the treatment of AIDS or AIDS related complex.
  • a human or animal patient in need of such treatment may be treated by a method comprising the administration thereto of one of the present compounds .
  • the present compounds can be administered in a variety of dosage forms, for example orally such as in the form of tablets, capsules, sugar- or film-coated tablets, liquid solutions or suspensions or parenterally, for example intramuscularly, intravenously or subcutaneously.
  • the present compounds may therefore be given by injection or infusion.
  • the dosage depends on a variety of factors including the age, weight and condition of the patient and the route of administration. Typically, however, the dosage adopted for each route of administration when a compound of the invention is administered alone to adult humans is 0.001 to 50 mg/kg, most commonly in the range of 0.01 to 5 mg/kg, body weight. Such a dosage may be given, for example, from 1 to 5 times daily by bolus infusion, infusion over several hours and/or repeated administration.
  • a piperazinedione derivative of formula (I) or a pharmaceutically acceptable salt thereof is formulated for use as a pharmaceutical or veterinary composition also comprising a pharmaceutically or veterinarily acceptable carrier or diluent.
  • the compositions are typically prepared following conventional methods and are administered in a pharmaceutically or veterinarily suitable form.
  • An agent for use as a modulator of multi-drug resistance comprising any one of the present compounds is therefore provided.
  • the solid oral forms may contain, together with the active compound, diluents such as lactose, dextrose, saccharose, cellulose, corn starch or potato starch; lubricants such as silica, talc, stearic acid, magnesium or calcium stearate and/or polyethylene glycols; binding agents such as starches, arabic gums, gelatin, methylcellulose, carboxymethylcellulose, or polyvinyl pyrrolidone; disintegrating agents such as starch, alginic acid, alginates or sodium starch glycolate; effervescing mixtures; dyestuffs, sweeteners; wetting agents such as lecithin, polysorbates, lauryl sulphates.
  • diluents such as lactose, dextrose, saccharose, cellulose, corn starch or potato starch
  • lubricants such as silica, talc, stearic acid, magnesium or calcium stearate and/or polyethylene glycols
  • Liquid dispersions for oral administration may be syrups, emulsions and suspensions.
  • the syrups may contain as carrier, for example, saccharose or saccharose with glycerol and/or mannitol and/or sorbitol.
  • a syrup for diabetic patients can contain as carriers only products, for example sorbitol, which do not metabolise to glucose or which only metabolise a very small amount to glucose.
  • the suspensions and the emulsions may contain as carrier, for example, a natural gum, agar, sodium alginate, pectin, methylcellulose, carboxymethylcellulose or polyvinyl alcohol .
  • Suspensions or solutions for intramuscular injections may contain, together with the active compound, a pharmaceutically acceptable carrier such as sterile water, olive oil, ethyl oleate, glycols such as propylene glycol, and, if desired, a suitable amount of lidocaine hydrochloride .
  • a pharmaceutically acceptable carrier such as sterile water, olive oil, ethyl oleate, glycols such as propylene glycol, and, if desired, a suitable amount of lidocaine hydrochloride .
  • Some of the present compounds are insoluble in water. Such compounds may be encapsulated within liposomes .
  • Method B 4-diacetyl-2, 5-piperazinedione was treated with a series of benzaldehydes R ⁇ CHO, where R 1 is as listed in table IB, in the presence of potassium t-butoxide in t- butanol-THF (1:1) at 0°C.
  • the reaction mixture was allowed to warm to room temperature for the time indicated in the table. Recrystallisation, which was optional, was conducted using the indicated solvent.
  • Method E Compound 1.1, described in Reference Example 1, was treated in DMF with sodium hydride and 2-dimethylaminoethyl chloride hydrochloride at 0°C. The reaction mixture was warmed to 20°C, and then further warmed to 80°C, over a period of 5 hours. The product was purified by recrystallisation from 1% MeOH in EtOAc to give 2.41 in 32% yield, which is a compound of formula (II) wherein R 2 is -CH 2 NMe 2 .
  • Method F Compound 1.1, described in Reference Example 1, was treated in acetonitrile with Cs 2 C0 3 and ethyl bromoacetate at -20°C. The reaction mixture was warmed to 20°C for 2 hours. The product was purified by flash chromatography using EtOAc-hexane (1:2) to give 2.42 in 35% yield, which is a compound of formula (II) wherein R 2 is -C0 2 Et.
  • 4-formylbenzoyl chloride was prepared by treating 4- formylbenzoic acid with thionyl chloride in toluene under reflux. It was then treated with compound 3.4, prepared according to Reference Example 5, in CH 2 C1 2 in the presence of Et 3 N at a temperature of about 0°C and allowed to warm to room temperature, to afford the following compound 4.2 in 53% yield:
  • Example 2 The compounds prepared in Example 2 were converted to the corresponding hydrochloride salts by treatment with gaseous HCI in THF.
  • Example 4 Selected compounds prepared in Example 4 were converted to the corresponding hydrochloride salts by treatment with gaseous HCI in CH,Cl 2 .
  • the hydrochloride denoted in Table 5 below by the suffix ".HCI” was in some cases then recrystallised as shown in the table.
  • Example 7 Pharmaceutical Composition Tablets, each weighing 0.15 g and containing 25 mg of a compound of formula (I) or salt thereof can be manufactured as follows:
  • the compound of formula (I) or salt thereof, lactose and half of the corn starch are mixed. The mixture is then forced through a sieve 0.5 mm mesh size. Corn starch (10 g) is suspended in warm water (90 ml) . The resulting paste is used to granulate the powder. The granulate is dried and broken up into small fragments on a sieve of 1.4 mm mesh size. The remaining quantity of starch, talc and magnesium stearate is added, carefully mixed and processed into tablets.
  • Example 8 Testing of compounds of formula (I) and their salts as modulators of MDR
  • EMT6 mouse mammary carcinoma cell line and the MDR resistant subline AR 1.0 were cultured in RPMI 1640 medium containing 10% foetal calf serum and 2mM glutamine at 37°C in 5% C0 2 .
  • Cells were passaged between 1 in 200 and 1 in 2000 in the case of the parental cell line and between 1 in 20 and 1 in 200 in the case of the MDR resistant subline, after trypsinisation (0.25% trypsin, 0.2gl " ⁇ EDTA) .
  • Drug accumulation assay AR 1.0 cells were seeded into 96 well opaque culture plates (Canberra Packard) .
  • the assay medium contained a mixture of tritiated Daunorubicin (DNR) , a cytotoxic agent, and unlabelled DNR (0.3 ⁇ Ci/ml; 2 ⁇ M) .
  • DNR tritiated Daunorubicin
  • Compounds of formula I were serially diluted in assay medium over a range of concentrations from 5 nM to 100 ⁇ M. The cells were incubated at 37°C for 1 hr before washing and determination of cell associated radioactivity. Results are expressed as % maximum accumulation where 100% accumulation is that observed in the presence of the known RMA verapamil at a concentration of 100 ⁇ M or as an IC E0 .

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
EP95941797A 1994-12-23 1995-12-22 Piperazine 2,5 dione derivatives as modulators of multi-drug resistance Withdrawn EP0799222A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9426224.3A GB9426224D0 (en) 1994-12-23 1994-12-23 Pharmaceutical compounds
GB9426224 1994-12-23
PCT/GB1995/003027 WO1996020190A1 (en) 1994-12-23 1995-12-22 Piperazine 2,5 dione derivatives as modulators of multi-drug resistance

Publications (1)

Publication Number Publication Date
EP0799222A1 true EP0799222A1 (en) 1997-10-08

Family

ID=10766589

Family Applications (1)

Application Number Title Priority Date Filing Date
EP95941797A Withdrawn EP0799222A1 (en) 1994-12-23 1995-12-22 Piperazine 2,5 dione derivatives as modulators of multi-drug resistance

Country Status (19)

Country Link
EP (1) EP0799222A1 (cs)
JP (1) JPH10511384A (cs)
CN (1) CN1175253A (cs)
AU (1) AU698828B2 (cs)
BG (1) BG101602A (cs)
BR (1) BR9510410A (cs)
CA (1) CA2207500A1 (cs)
CZ (1) CZ190097A3 (cs)
FI (1) FI972660L (cs)
GB (1) GB9426224D0 (cs)
HU (1) HUT77943A (cs)
IL (1) IL116525A0 (cs)
NO (1) NO972937D0 (cs)
NZ (1) NZ297847A (cs)
PL (1) PL320916A1 (cs)
SK (1) SK83697A3 (cs)
TW (1) TW358094B (cs)
WO (1) WO1996020190A1 (cs)
ZA (1) ZA9510909B (cs)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0001531A3 (en) * 1996-10-18 2000-09-28 Xenova Ltd Slough Anthranilic acid derivatives as multi drug resistance modulators
GB9717576D0 (en) * 1997-08-19 1997-10-22 Xenova Ltd Pharmaceutical compounds
GB9708805D0 (en) 1997-05-01 1997-06-25 Smithkline Beecham Plc Compounds
GB9810876D0 (en) 1998-05-20 1998-07-22 Smithkline Beecham Plc Compounds
KR20010085898A (ko) 1998-10-08 2001-09-07 피터 기딩스 도파민 ｄ3 수용체 조절제 (정신병 치료제)로서 유용한테트라히드로벤즈아제핀 유도체
BR0017067A (pt) * 2000-01-18 2002-10-22 Nereus Pharmaceuticals Inc Inibidor de divisão de célula, desidrogenase, método para a produção de um inibidor de divisão de célula e composto
AU2001288829A1 (en) 2000-09-06 2002-03-22 Ap Pharma, Inc. Degradable polyacetal polymers
US6693099B2 (en) 2000-10-17 2004-02-17 The Procter & Gamble Company Substituted piperazine compounds optionally containing a quinolyl moiety for treating multidrug resistance
US7919497B2 (en) 2002-08-02 2011-04-05 Nereus Pharmaceuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
ATE374767T1 (de) 2002-08-02 2007-10-15 Nereus Pharmaceuticals Inc Dehydrophenylahistine und analoge davon sowie ein verfahren zur herstellung von dehydrophenylahistinen und analogen davon
US7935704B2 (en) 2003-08-01 2011-05-03 Nereus Pharmaceuticals, Inc. Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
US8129527B2 (en) 2006-11-03 2012-03-06 Nereus Pharmacuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
CN103396372B (zh) * 2013-08-09 2015-05-20 中国科学院南海海洋研究所 一类2,5-二酮哌嗪衍生物及其制备方法和在制备抗海洋污损生物防除剂中的应用
JP6904570B2 (ja) 2015-03-06 2021-07-21 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド 脳腫瘍の治療方法
KR102626155B1 (ko) 2015-03-06 2024-01-17 비욘드스프링 파마수티컬스, 인코포레이티드. Ras 돌연변이와 관련된 암의 치료 방법
CA2991059C (en) 2015-07-13 2024-01-16 Beyondspring Pharmaceuticals, Inc. Plinabulin monohydrate polymorphs
JP2019511565A (ja) 2016-02-08 2019-04-25 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド ツカレゾールまたはそのアナログを含む組成物
US11229642B2 (en) 2016-06-06 2022-01-25 Beyondspring Pharmaceuticals, Inc. Composition and method for reducing neutropenia
CN110431135A (zh) 2017-01-06 2019-11-08 大连万春布林医药有限公司 微管蛋白结合化合物及其治疗用途
IL268305B2 (en) 2017-02-01 2024-08-01 Beyondspring Pharmaceuticals Inc Plinabulin in combination with one or more g-csf drug for use in the therapeutic treatment of docetaxel-induced
JP7350015B2 (ja) 2018-01-24 2023-09-25 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド プリナブリンの投与による血小板減少症を軽減するための組成物および方法
EP4319751A4 (en) 2021-04-09 2025-02-26 Beyondspring Pharmaceuticals, Inc. THERAPEUTIC COMPOSITIONS AND METHODS FOR THE TREATING OF TUMORS

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994001408A1 (en) * 1992-07-10 1994-01-20 Laboratoires Glaxo S.A. Anilide derivatives
GB9217331D0 (en) * 1992-08-14 1992-09-30 Xenova Ltd Pharmaceutical compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9620190A1 *

Also Published As

Publication number Publication date
WO1996020190A1 (en) 1996-07-04
FI972660A7 (fi) 1997-08-22
CA2207500A1 (en) 1996-07-04
NO972937L (no) 1997-06-23
BR9510410A (pt) 1999-09-08
AU4310096A (en) 1996-07-19
FI972660L (fi) 1997-08-22
CN1175253A (zh) 1998-03-04
PL320916A1 (en) 1997-11-10
GB9426224D0 (en) 1995-02-22
IL116525A0 (en) 1996-03-31
ZA9510909B (en) 1996-08-30
JPH10511384A (ja) 1998-11-04
SK83697A3 (en) 1998-05-06
NZ297847A (en) 1999-04-29
NO972937D0 (no) 1997-06-23
HUT77943A (hu) 1998-12-28
FI972660A0 (fi) 1997-06-19
AU698828B2 (en) 1998-11-05
CZ190097A3 (cs) 1998-01-14
BG101602A (en) 1998-02-27
TW358094B (en) 1999-05-11

Similar Documents

Publication Publication Date Title
EP0799222A1 (en) Piperazine 2,5 dione derivatives as modulators of multi-drug resistance
DE60132235T2 (de) Tetrahydrobenzazepin-derivate zur verwendung als dopamin-d3-rezeptor-modulatoren (antipsychotische mittel)
US5852018A (en) Pharmaceutical piperazine compounds
NO313591B1 (no) Antranilinsyrederivater som modulatorer av multimedikamentresistens
JP5778297B2 (ja) 癌治療用のｈｄａｃ阻害剤としての新規４−アミノ−ｎ−ヒドロキシ−ベンズアミド
JP2013506714A (ja) ピロリジンｇｐｒ４０モジュレーター
JPH10500425A (ja) 薬学的なジケトピペラジン化合物
EA001280B1 (ru) Замещенные n-[(аминоиминометил или аминометил)фенил] пропиламиды
US9409864B2 (en) Sulfonamide TRPA1 receptor antagonists
EP0626954A1 (en) Benzocycloheptenes, benzoxepines and benzothiepines
EP0799210B1 (en) Piperazine-2,5-dione derivatives as modulators of multidrug resistance
AU2004285913A1 (en) 3-(4-aminophenyl) thienopyrimid-4-one derivatives as MCH R1 antagonists for the treatment of obesity, diabetes, depression and anxiety
HUT53606A (en) Process for production of chained compositions and medical compositions containing them
WO2011130163A1 (en) Substituted hydroxamic acids and uses thereof
Sheppard et al. 3-(2-(3-Pyridinyl) thiazolidin-4-oyl) indoles, a novel series of platelet activating factor antagonists
WO1996020179A1 (en) Piperazine-2,5-dione derivatives as modulators of multi-drug resistance
JPH07505393A (ja) 非橋渡しビスアリールカルビノール誘導体，組成物および使用法
WO2008022747A1 (en) Tricyclic lactam derivatives, their manufacture and use as pharmaceutical agents
WO2019082910A1 (ja) バソプレシン受容体拮抗剤
FI76794B (fi) Foerfarande foer framstaellning av nya terapeutiskt anvaendbara spirotiazolidindionderivat.
US5861400A (en) Pharmaceutical compounds
JPH06122677A (ja) 光学活性なカルボン酸アミド誘導体
JP3786983B2 (ja) ピロリジノン誘導体
MXPA03002447A (es) Imidazoles sustituidos como agonistas o antagonistas duales h1 y h3 de histamina.
GB2324301A (en) Pharmaceutically-active Piperazinedione Compounds

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19970714

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 19981012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19990423